

From: Boris Nikolic <[REDACTED]>
To: "[REDACTED]" <[REDACTED]>
CC: "jeevacation@gmail.com" <jeevacation@gmail.com>
Subject: RE: Re:
Date: Tue, 06 Nov 2018 16:19:09 +0000

Hi Harry,

I am in Seattle this week and last night I had chance to meet with few people from BMGF. I was told that BMGF will not fund (directly) female condom projects going forward. There were some projects several years back but these are now terminated.

As I was suspecting, for the most part it is an issue of procurement so this is now in hands of partners such as PATH, PSI

Sorry that I can't be of more help

Best

Boris

From: [REDACTED] <[REDACTED]>
Sent: Saturday, November 3, 2018 11:32 AM
To: Boris Nikolic <[REDACTED]>
Cc: jeevacation@gmail.com
Subject: Re:

Hi Boris

Currently The Female Health division of VERU supplies approximately 50 million Female Condoms worldwide. BMGF has never funded the FC2 Female condom. I don't know why this is the case.

The FC2 female condom is the most demanded and utilized female condom worldwide. It is supplied throughout Africa via UNFPA and bought directly by South Africa.

Funding by UNFPA has dramatically decreased and we are unable to supply certain countries that have requested the female condom.

For example, the following countries have requested the FC2 female condom but we are unable to supply:

Uganda : 3 million units

Ghana: 1 million units

Botswana: 1 million units

Tunesia: 1 million units

Sierra Leone: 500,000 units

Bolivia: 500,000 units

Tanzania: 1 million units

Haiti: 500,000 units

Ethiopia: 1 million units

Congo DR: 2 million units

Boris, can you introduce me to the right person at BMGF to see if we can get grants to provide FC2 female condoms to all women who request them in Africa.

Also attached is more information regarding the FC2 female condom.

Would like to continue the conversation.

Sincerely,

Harry

-----Original Message-----

From: Boris Nikolic <[REDACTED]>

To: harryfish <[REDACTED]>

Cc: jeevacation <jeevacation@gmail.com>

Sent: Sat, Nov 3, 2018 1:27 pm

Subject: RE: Re:

Thank you Harry!

Again – great meeting you. I am still laughing re inherited STD.

Finally I had chance to read your slide deck. VERU is indeed very interesting company – congrats!

You have an interesting mix of Urology specialty drugs (which I see as a low risk) and Prostate cancer drugs.

Unfortunately my fund (<https://www.biomaticscapital.com/>) is only focused (and restricted to investing) on private companies.

Mid-end of the next year I am going to fundraise a crossover fund which would allow me to invest in both private and publicly listed companies; nevertheless, I am now unable to invest in companies such as VERU – despite how interesting they might be.

I looked at a female condom. I think that PATH supported a number of related projects.

<https://www.path.org/articles/seven-secrets-of-the-female-condom/>

As you might know BMGF is the main donor to PATH – this is why I mentioned it.

Also BMGF founded several smaller grants (GCE) re female condoms <https://www.gatesfoundation.org/Media-Center/Press-Releases/2014/06/GCE-Round-12>

In addition, there were grants to Imperial College in London, HealthRock etc.

All of these are relatively old grants that ended. My guess is that all female condom more mature projects transitioned to PATH.

Also I see that PSI has been funding marketing and delivery <https://www.psi.org/2018/03/fresh-start-female-condom-marketing/>

Please let me know if there is anything else I can be of help to you.

Hope to see you soon in NYC

Best

Boris

From: [REDACTED] <[REDACTED]>
Sent: Thursday, November 1, 2018 5:34 PM
To: Boris Nikolic <[REDACTED]>; jeevacation@gmail.com
Subject: Re:

Jeffrey thanks for introducing me to Boris.

Boris, great meeting you as well.
Attached is the most recent deck for VERU (NASDAQ: VERU), www.verupharma.com .
In addition please look at www.femalecondom.com. We merged with The Female Health Company which sells the FC2 Female Condom to the public sector in Africa and Brazil via UNFPA and USAID. We just recently introduced this condom into the US market mainly via telemedicine.

Would love to meet and discuss further.

Sincerely,
Harry

Harry Fisch MD
[REDACTED]

-----Original Message-----

From: Boris Nikolic <[REDACTED]>
To: J <jeevacation@gmail.com>; Harry Fisch <[REDACTED]>
Sent: Thu, Nov 1, 2018 4:13 pm
Subject: RE:

Thank you J!

Great meeting you Harry!
Looking forward to seeing you again.
Please send me something re your company.

Best

Boris

From: J <jeevacation@gmail.com>
Sent: Thursday, November 1, 2018 3:15 PM
To: Boris Nikolic <[REDACTED]>; Harry Fisch <[REDACTED]>
Subject:

harry boris , boris harry

--

please note

The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of JEE
Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by

return e-mail or by e-mail to jeevacation@gmail.com, and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved